I think this paper https://www.cell.com/iscience/fulltext/S2589-0042(24)01630-4
is great. The source data includes cultures, mice, and humans.
TLDR points:
* even an up to date vaccine gives weak protection against JN.1
* variants are practically different diseases from each other, with 5x differences in spike expression, evasiveness, cell-cell fusion, and other major traits
The big dump:
* Cell-cell fusion was 2-5x more common in Ancestral, Beta, and Delta compared to currently circulating strains (Fig 1.G)
* note vaccination + BA.5 update + XBB update STILL gives almost no neutralizing antibodies against JN.1 (Fig 5)
"JN.1 is reported to be more immune evasive than its predecessors to evade the vaccine- or breakthrough infection-mediated neutralizing antibodies"
"BF.7, BA.2 and its descendants BA.2.86 and JN.1 exhibited up to 50% of lower total expression than other omicron spikes"
"BA.2.86 and JN.1, which showed 3- and 4-fold elevated viral infection than WA01/2020 pseudovirus, respectively, despite lower spike incorporations into pseudovirions than the ancestral strain"
"the JN.1 spike showed approximately 80% reduced expression compared with that of the ancestral strain"
"all variants showed improved binding affinity to ACE2 than the WA01/2020 spike, and intriguingly, the JN.1 and BA.2.86 demonstrated the strongest ACE2 binding after normalization."
"The ancestral WA01/2020 and early variant strains Beta and Delta showed strong cell fusion capacity, while omicron variants showed much reduced cell-cell fusion"
"Overall, the JN.1 spike appears to show reduced expression and incorporation into the pseudovirions, but demonstrated surprisingly greater viral infectivity."
"homologous immunizations with BQ.1.1 elicited a strong binding antibody titer against BA.4/5, XBB, and EG.5.1, while homologous immunizations with XBB elicited binding antibodies only against XBB strain"
"Of particular interest, none of the immunization combinations were able to induce binding or neutralizing antibodies against BA2.86 and JN.1."
"It is noteworthy that none of these vaccines induced cross-antibody against BA.2.86 and JN.1."
"Again, none of the groups induced cross-mucosal antibodies against BA.2.86 and JN.1, even though Ad5-BF. 7 induced modest NAb titers against JN.1"
"We noted a clear booster effect for all variants except JN.1 by BA.5 and/or XBB breakthrough infections. In general, JN.1 showed a rough 3.3- and 5.5-fold reduced NAb in breakthrough-infected individuals when compared with BA.2.86."
"relatively balanced and cross-reactive antibody responses were induced by XBB- and EG.5.1-adapted boosters, which were, however, less reactive against BA.2.86 and JN.1"
"immune imprinting, a phenomenon where previous exposure could limit the generation of de novo immune responses against variant infections or the response to the next-generation vaccines, further completes the situations and therefore requires a discrete assessment"
"Despite that homologous BQ.1.1+BQ.1.1 and heterologous WA01/2020 and BA.5 prime-boost immunization elicited binding antibody titers, none of the combinations resulted in cross-reactive antibodies against BA.2.86 and JN.1. In line with this, human cohorts with three inactivated vaccine or two adenoviral vectored vaccine immunizations showed minimal serum neutralizing capacity against JN.1 (Figure 5), indicating the susceptibility of this population to JN.1 breakthrough infections."
So stack those #SwissCheeseModel defenses!
h/t to @CastlTrAstonDrs; thanks Doc!
#CovidIsNotOver #SARSCoV2 #SARS2 #COVID19 #COVID #pandemic #covidsafety #WearAMask #maskUp #CleanTheAir #JN1